Publication date: 22nd April 2022
The best known and most widespread neurodegenerative illnesses are Alzheimer's (AD) and Parkinson's disease (PD). The conventional treatments developed offer relatively little symptomatic benefit, and remain palliative, consequently the research and development of more powerful and effective pharmacological tools for these diseases are of daily interest. Arundic acid is a new derivative of valproic acid, both are potential drugs for the treatment of AD and PD (Landmark, 2008). Some studies have shown that astrocytes are the primary target of these two agents (Chen et al. 2006, Asano et al. 2005); however, the mechanism by which they carry out their glioprotective action as well as their toxicological profile is not fully defined. In this work, valproic and arundic acids have been tested in two animal models: Hydra vulgaris and Nematostella vectensis. These small polyps are considered excellent model organisms for both in vivo and in vitro studies, in fact they are equipped with a simple anatomical structure and a simple neural system that allows studies of signal transmission. Furthermore, the transparency of the body allows bioimaging studies, to monitoring the localization of fluorescent and / or metal-based nanomaterial. With the aim to identify the toxicological profile and the mechanism of action of arundic and valproic acids, we investigated the morpho-functional response and gene expression. The preliminary data here reported, are the starting point for chitosan nanoformulation of these drugs, with the purpose of designing new pharmaceutical forms that improve administration and compliance in particular the palatability given that the use of arundic acid in clinical administration has encountered numerous obstacles, related to the difficult administration of this compound and its unpleasant taste.
funding: International Exchanges 2019 Round 2 della Royal Society -London n° IES\R2\192256